

## Epidemic Malaria Control Programme (Western Rajasthan 1984, Assam, 1995)

During Epidemic Malarial control programmes at Rajasthan and Assam approximately 3,600 and 10,000 P-vivax cases were treated respectively. Clinical improvement was observed in almost all cases. Positive P. falciparum was observed in some cases and parasite clearance and clinical improvement was found in few number of cases.

**Side Effects :** No side/toxic effect in prescribed doses

**Dose :** As mentioned below or as directed by the physician.

**Adult :** 4 tablets (500 mg per tab.), thrice daily for 5-7 days

**Children (5-12 yrs) :** 2 tablets, thrice daily for 5-7 days

**Infants (below 5 yrs) :** Powder of 1 tablet with honey, three times a day

**IPR Status** - Patent No. 152863

Further information can be obtained from :

Director General


Central Council for Research in Ayurvedic Sciences  
No. 61-65, Institutional Area, Opp. 'D'-Block, Janakpuri, New Delhi-110058  
Telephone : +91-11-28525520/28524457, Fax : +91-11-28520748  
E-mail : dg-ccras@nic.in  
Website : www.ccras.nic.in  
www.indianmedicine.nic.in

© C.C.R.A.S. 2014

This document is meant for publicity and distribution only. Not for commercial purposes. Reproduction of this material is possible only after taking permission from Director General C.C.R.A.S.

# AYUSH - 64

## An Ayurvedic Anti-Malarial Drug



CENTRAL COUNCIL FOR RESEARCH IN AYURVEDIC SCIENCES  
Ministry of AYUSH  
(Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homoeopathy)  
Government of India

An Ayurvedic Anti-Malarial Drug



Kuberaksa (*Caesalpinia crista* Linn.)



Chirayata (*Swertia chirata* Buch-Ham)



Katuki (*Picrorhiza kurroa* Royle)

### Background

Among all tropical diseases, Malaria is one of the most prevalent, destructive, widely spread disease condition and well known to Ayurvedic Physicians since ancient times. Descriptions concerning aetiopathogenesis, clinical features and line of management are detailed under Vishmajvara in ancient classical literature of Ayurveda. Considering its wide prevalence and developing drug resistance to malarial parasite, CCRAS has developed a polyherbal non-toxic, anti-malarial drug- Ayush-64 through extensive pharmacological, toxicological and clinical studies. This has been patented by the Council through National Research Development Corporation, New Delhi

## AYUSH - 64

### Composition

Each tablet contains :

Saptaparna Stem Bark ( <i>Alstonia sholaris</i> )	Aqueous Extract	100 mg
Katuki Root ( <i>Picrorhiza kurroa</i> )	-do-	100 mg
Chirayata Whole plant ( <i>Swertia chirata</i> )	-do-	100 mg
Kuberaksa Seed ( <i>Caesalpinia crista</i> )	Power	200 mg

### Pharmacological and Toxicological Studies

Ayush-64 in the dose of 500 mg per kg body weight for 12 weeks has been proved safe and non-toxic.

### Clinical Trials

**General Clinical Trial :** Clinical trials of Ayush-64 were conducted on 1442 positive cases of malaria at various Research institutes and Centres of the Council located in different parts of the country. The response of treatment was 89% and the findings were comparable with known Anti-malarial drugs-Chloroquine and Primaquine.

**Double Blind studies :** OPD & IPD level double blind clinical studies were conducted on 178 patients which revealed that the drug is effective in 95.4% of patients. The drug showed effect both against fever and the Parasite.

An Ayurvedic Anti-Malarial Drug